A new obesity-focused biotech is heading to Wall Street. Kalohexis, spun out of Endevica Bio earlier this year, has confidentially filed for a U.S. IPO. The company is developing oral peptide drugs targeting the melanocortin system to treat obesity and cancer-related cachexia.
A new obesity-focused biotech is heading to Wall Street. Kalohexis, a clinical-stage biotechnology company spun out of Endevica Bio in March 2026, has confidentially filed for a U.S. initial public offering. The move adds to a growing rebound in IPO market activity, though terms of the offering have not yet been disclosed.
The company is targeting metabolic disorders through the body's melanocortin (MC) system — a natural regulator of metabolic balance. Its pipeline consists of proprietary peptides designed to safely engage central regulatory receptors in this system.
Quick Facts:
Why it matters: As the obesity drug market heats up, Kalohexis represents a novel mechanistic approach distinct from GLP-1 therapies. Its dual focus on obesity and cancer cachexia could broaden its clinical and commercial appeal if its pipeline advances successfully.
